{"organizations": [], "uuid": "f91ee6797287490ca8e4880dae960bac87a8f4f7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-janssen-to-acquire-benevir-biophar/brief-janssen-to-acquire-benevir-biopharm-to-advance-immunotherapy-regimens-idUSASC09YXY", "country": "US", "domain_rank": 408, "title": "BRIEF-Janssen To Acquire Benevir Biopharm To Advance Immunotherapy Regimens", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T14:07:00.000+03:00", "replies_count": 0, "uuid": "f91ee6797287490ca8e4880dae960bac87a8f4f7"}, "author": "", "url": "https://www.reuters.com/article/brief-janssen-to-acquire-benevir-biophar/brief-janssen-to-acquire-benevir-biopharm-to-advance-immunotherapy-regimens-idUSASC09YXY", "ord_in_thread": 0, "title": "BRIEF-Janssen To Acquire Benevir Biopharm To Advance Immunotherapy Regimens", "locations": [], "entities": {"persons": [{"name": "benevir", "sentiment": "none"}, {"name": "johnson", "sentiment": "none"}, {"name": "janssen", "sentiment": "none"}], "locations": [{"name": "maryland", "sentiment": "none"}, {"name": "rockville", "sentiment": "none"}], "organizations": [{"name": "biopharm", "sentiment": "none"}, {"name": "immunotherapy regimens reuters", "sentiment": "none"}, {"name": "johnson & johnson", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2, 2018 / 11:08 AM / Updated 10 minutes ago BRIEF-Janssen To Acquire Benevir Biopharm To Advance Immunotherapy Regimens Reuters Staff\nMay 2 (Reuters) - Johnson & Johnson:\n* JANSSEN TO ACQUIRE BENEVIR BIOPHARM TO ADVANCE IMMUNOTHERAPY REGIMENS\n* JANSSEN BIOTECH- ENTERED INTO A DEFINITIVE AGREEMENT UNDER WHICH IT WILL ACQUIRE BENEVIR BIOPHARM\n* JANSSEN BIOTECH - BENEVIR WILL MAINTAIN A RESEARCH PRESENCE IN ROCKVILLE, MARYLAND AND BECOME PART OF JANSSEN ONCOLOGY THERAPEUTIC AREA\n* JANSSEN BIOTECH - JOHNSON & JOHNSON INNOVATION LLC FACILITATED TRANSACTION Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-02T14:07:00.000+03:00", "crawled": "2018-05-02T14:25:59.013+03:00", "highlightTitle": ""}